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Introduction: The aim of this study was to synthesize and perform a side-by-side comparison of two new
tumor-angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and
64Cu-NODAGA-E[c(RGDyK)]2 in vivo using
human xenograft tumors in mice. Human radiation burden was estimated to evaluate potential for future use
as clinical PET tracers for imaging of neo-angiogenesis.
Methods: A 68Ge/68Ga generator was used for the synthesis of 68Ga-NODAGA-E[c(RGDyK)]2. 68Ga and 64Cu
labeled NODAGA-E[c(RGDyK)]2 tracers were administrated in nude mice bearing either human glioblastoma
(U87MG) or human neuroendocrine (H727) xenograft tumors. PET/CT scans at 3 time points were used for
calculating the tracer uptake in tumors (%ID/g), integrin αVβ3 target speciﬁcity was shown by blocking with
cold NODAGA-E[c(RGDyK)]2, and biodistribution in normal organs were also examined. From biodistribution
data in mice human radiation-absorbed doses were estimated using OLINDA/EXM software.
Results: 68Ga-NODAGA-E[c(RGDyK)]2 was synthesized with a radiochemical purity of 89%–99% and a speciﬁc
activity (SA) of 16–153 MBq/nmol. 64Cu-NODAGA-E[c(RGDyK)]2 had a purity of 92%–99% and an SA of 64–
78 MBq/nmol.
Both tracers showed similar uptake in xenograft tumors 1 h after injection (U87MG: 2.23 vs. 2.31%ID/g; H727:
1.53 vs. 1.48%ID/g). Both RGD dimers showed similar tracer uptake in non-tumoral tissues and a human
radiation burden of less than 10 mSv with an administered dose of 200 MBq was estimated.
Conclusion: 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 can be easily synthesized and
are both promising candidates for PET imaging of integrin αVβ3 positive tumor cells. 68Ga-NODAGA-E
[c(RGDyK)]2 showed slightly more stable tumor retention. With the advantage of in-house commercially
68Ge/68Ga generators, 68Ga-NODAGA-E[c(RGDyK)]2 may be the best choice for future clinical PET imaging
in humans.
© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Angiogenesis, the formation of new blood vessels, plays an
important role inmany pathological processes such as cancer. Integrin
αVβ3 is a cell adhesion molecule and is highly expressed on activated
endothelial cells and tumor cells, but not on resting endothelial cells.
During the past decade many preclinical studies and clinical trials
have conﬁrmed the importance of integrinαVβ3 as a speciﬁc target for
neo-angiogenesis, due to its role in the tumor growth and metastasis
[1–3]. Extracellular matrix (ECM) proteins such as vitronectin,
ﬁbrinogen and ﬁbronectin interact with integrin αVβ3 via the amino
acid sequence Arg-Gly-Asp (RGD) [4–6]. Often reported RGD peptides
used for radiolabeling are the cyclic pentapeptides cyclo(Arg-Gly-
Asp-D-Phe-Lys), c(RGDfK) and cyclo(Arg-Gly-Asp-D-Tyr-Lys),
c(RGDyK), which only differ with one amino acid [7–23]. Multimeric45 35 32 75 46.
-NC-ND license.c(RGDxK) (x = y or f), as dimeric, tetrameric and octameric
c(RGDxK), has been investigated to optimize the tracer uptake in
integrin αVβ3 positive tumor cells. Afﬁnity for integrin αVβ3 is
enhanced and tracer uptake improves when peptide multiplicity
increases, however also the tracer uptake in organs increases
signiﬁcantly, resulting in poor Tumor-to-Organ ratios. The conclusion
is therefore that dimeric c(RGDxK) tracers may be the optimal choice
with respect to tumor-to-Background ratios [19].
CyclicRGDpeptides targeting integrinαVβ3 in various tumormodels
and labeled with positron-emitting radionuclides (18 F, 68Ga, 64Cu) for
positron emission tomography (PET) have been reported [7–23].
Several bifunctional chelators (BFC) such as 1,4,7,10-tetraazacyclodo-
decane-N,N´,N´´,N´´´-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-
N,N´;N´´-triacetic acid (NOTA) and 1,4,7-triazacyclononane-1-glutaric
acid-4,7-diacetic acid (NODAGA) have been conjugated to RGD
peptides, where NODAGA is particularly useful for 68Ga- and 64Cu-
labeling due to high hydrophilicity and in vivo stability of its 68Ga
and 64Cu chelates [19].
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by-side comparison of the two new tumor-angiogenesis PET tracers
68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 using
human glioblastoma (U87MG) and human neuroendocrine (H727)
xenograft tumors inmice.We compared the tracer uptake of the 68Ga-
and 64Cu-labeled NODAGA-E[c(RGDyK)]2, for 68Ga-tracer with “high”
and “low” speciﬁc radioactivity, investigated the speciﬁcity of the
dimeric c(RGDyK) by blocking with cold peptide, performed biodis-
tribution studies, and estimated the radiation burden in humans by
projecting radiation dosimetry data from mice.
2. Materials and methods
2.1. General
The 50 mCi 68Ge/68Ga generator was purchased from Eckert &
Ziegler (Berlin, Germany) andwas elutedwith 0.1 N HCl (Biochemical
grade; Fluka) using the fractionated elution approach. 64CuCl2 was
produced at DTU-Risoe, Roskilde, Denmark [24]. NODAGA-c(RGDyK)2
was purchased from ABX GmbH (advanced biochemical compounds,
Radeberg, Germany). Sodium acetate, ammonium acetate and
TraceSELECT water were purchased from Sigma-Aldrich. For high-
performance liquid chromatography (HPLC) analysis a Dionex P580
pump with a PDA-100 detector and an in-line Scansys radioactivity
detector was used. HPLC analysis was performed with a Jupiter 4u
Proteo 90A, 250 × 4.6 mm (Phenomenex) and 1.5 mL/min ﬂow. HPLC
eluents were: A—90:10 (v/v) water: acetonitrile containing 0.1%
triﬂuoroacetic acid; and B—90:10 (v/v) acetonitrile: water containing
0.1% triﬂuoroacetic acid. Gradient: 0–2 min 0% B, 2–7 min 40% B, and
7–9 min 0% B, 10 min 0% B.
2.2. Radiochemistry
2.2.1. 68Ga-NODAGA-E[c(RGDyK)]2 synthesis
68Ga (t1/2 = 68 min; Emax, β+ = 1.90 MeV (89%)) labeling was
performed using the fractionated method [24]. The 68Ge/68Ga
generator was eluted with 6 ml 0.1 N HCl into 6 tubes containing
1 ml each. The fraction with approximately 80% of the entire activity
(1 ml, 450–500 MBq) was transferred to a vial containing 2 or
20 nmol NODAGA-E[c(RGDyK)]2 acetate (Fig. 1) and 1 ml 0.7 M
NaOAc buffer (pH 5.2). The reaction mixture was left at room
temperature for 15 min, and the mixture was puriﬁed by C18 light
SepPak. HPLC analysis of the ﬁnal product revealed that the retention
time of 68Ga-NODAGA-E[c(RGDyK)]2 was 6.3 min.Fig. 1. Chemical structure of2.2.2. 64Cu-NODAGA-E[c(RGDyK)]2 synthesis
NODAGA-E[c(RGDyK)]2 (2 nmol) was mixed with 450 μL ammo-
nium acetate (0.1 M, pH 8.4), and 50 μL of 64CuCl2 (50–60 MBq) was
added (64Cu: t1/2 = 12.7 h; Emax, β+ = 0.653 MeV (18%)). The
solution was left at room temperature for 15 min. The product was
used without further puriﬁcation.
HPLC analysis of the ﬁnal product revealed that the retention time
of 64Cu-NODAGA-E[c(RGDyK)]2 was 6.5 min.
2.3. Cell lines and animal model
Human lung bronchus carcinoid, NCI-H727 and Human glioblas-
toma, U87MG both obtained from ATCC (American Type Culture
Collection, Manassas, VA, USA) were used. Cell lines were tested free
of Mycoplasma at the State Serum Institute, Copenhagen, Denmark
before taking into experiments. H727 cells were cultured in RPMI
(Roswell Park Memorial Institute) 1640 Medium with GlutaMAX™
(Gibco®, Life Technologies, NY, USA), U87MG in DMEM (Dulbecco's
Modiﬁed Eagle Medium), high glucose, also with GlutaMAX™
(Gibco®, Life Technologies, NY, USA). Both cell lines were supple-
mented with 10% (v/v) fetal calf serum (Biological Industries (BI),
Kibbutz Beit-Haemek, Israel) and 1% (v/v) penicillin–streptomycin
(Gibco®, Life Technologies, NY, USA) in 5% CO2 at 37°C.
Female NMRI (Naval Medical Research Institute) nude mice were
acquired from Taconic Europe, Lille Skensved, Denmark. Xenografts of
the twohuman cancer cell lineswere establishedby injectionof 100 μL
medium containing 1 × 107 cells, suspended in 100 μL Matrixgel™
Basement Membrane Matrix (BD Sciences, San José, CA, USA)
subcutaneously on the left and right ﬂanks, under anesthesia with
1:1 V/V Hypnorm® (Janssen Pharmaceutica NV, Beerse, Belgium)/
Dormicum® (Roche, Basel, Switzerland). When reaching a tumor
volume of approximate 100–300 mm3 3–4 weeks after inoculation,
the mice were enrolled in biodistribution, small animal PET/CT and
blocking studies. All animal experiments were performed under the
approval of the Danish Animal Welfare Council (2011/561-14).
2.4. Biodistribution studies
Micewere tail-vein injected with 4.4 ± 1.4 MBq (mean±SD) 68Ga-
NODAGA-E[c(RGDyK)]2 or 5.2 ± 1.2 MBq 64Cu-NODAGA-E
[c(RGDyK)]2 under sevoﬂourane anaesthesia. Biodistribution of 68Ga-
NODAGA-E[c(RGDyK)]2 was obtained at 1, 2 and 4 h post injection (h
pi), and of 64Cu-NODAGA-E[c(RGDyK)]2 at 1, 4 and 18 h pi (n = 4–6
mice in each group). Mice were sacriﬁced and major organs (liver,NODAGA-E[c(RGDyK)]2.
Fig. 2. Peptide amount versus radiochemical purity (before SepPak puriﬁcation) for
68Ga-NODAGA-E[c(RGDyK)]2. The minimum amount of peptide practical possible to
use was 2 nmol. Below 2 nmol the SepPak puriﬁcation was unreliable. Using 4 nmo
peptide higher and more reliable radiochemical yields were found. Data are shown as
mean ± SD; 2 nmol: 49.8% ± 27.0% (n = 15); 4 nmol: 89.6% ±6.0% (n = 3)
20 nmol: 97.1% ± 0.4% (n = 4); for 10 nmol (n = 1).
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and wet-weighed. The radioactivity was measured using a gamma-
counter (2480 Wizard®, Perkin Elmer, MA, USA). The results are
presented as percentage of injected dose per gram tissue (%ID/g).
2.5. Small animal PET and CT
2.5.1. Imaging experiments
Mice bearing U87MG and H727 tumors were scanned statically
with both 68Ga- and 64Cu-labeled NODAGA-E[c(RGDyK)]2 containing
2 nmol of peptide. PET scanswith 68Ga-labeled tracerwere performed
1, 2 and 4 h pi after tail-vein injection of 4.8 ± 0.9 MBq (mean±SD);
regarding 64Cu labeled tracer 1, 4 and 18 h pi with injection of 5.0 ±
1.0 MBq. Scan time was 15 and 20 min, respectively. n = 12–14
tumors for each xenograf tumor model at each scan time.
Preparations containing 20 nmol NODAGA-E[c(RGDyK)]2 were
also investigated with 68Ga-labeling. PET/CT static scans 1, 2 and 4 h
pi after injection of 4.9 ± 0.7 MBq (mean±SD) were performed on
mice bearing H727 or U87MG xenograf tumors (n = 10 of each tumor
type). The results are presented as percentage of injected dose per
gram tissue (%ID/g), and compared to the tracer uptake found in mice
(n = 12 of each tumor type) administrated with 68Ga-NODAGA-E
[c(RGDyK)]2.
All PET scans were performed using a small animal PET scanner
(MicroPET Focus 120, Siemens Medical Solutions, Knoxville, TN, USA).
The energy window for the emission PET scans was set to 350–
650 keV with a time resolution of 6 ns. The acquired emission dataset
was stored in list mode format and post-processed to 2 bytes
128 × 144 × 32 sinograms. The emission sinograms were recon-
structed using 3D Maximum a posteriori (MAP) algorithms resulting
in 4 bytes 256 × 256 × 95 images with a zoom factor of 1.443 and a
voxel size of 0.30 × 0.30 × 0.79 mm3. Resolution of the PET scanner
was 1.5 mm at center ﬁeld of view. The emission sinograms were
corrected for dead time and decay time, and the system calibrated to
provide the quantiﬁcation unity in Becquerel’s per cubic centimeter
(Bq/cc).
CT data were acquired using a small animal Computed Tomogra-
phy System (MicroCAT® II, Siemens Medical Solutions, USA). The X-
ray tube settings were voltage 60 kVp, current 500 μA, and exposure
time 430 ms per projection. A set of 360 projections was used for a full
360 scan. To increase sensitivity and to reduce the size of the datasets,
CT projections were binned by 4. The projections were reconstructed
using COBRA real-time reconstruction algorithm with the Shepp–
Logan ﬁlter into a 512 × 512 × 768 matrix with a voxel size of
0.092 × 0.092 × 0.092 mm3 [25].
2.5.2. Image analysis
68Ga- and 64Cu-NODAGA-E[c(RGDyK)]2 uptake in U87MG and
H727 tumorswas quantiﬁed using the image analysis software Inveon
Research Workplace (IRW; Siemens Medical Solutions, Malvern, PA,
USA). 3D regions of interest (ROIs) were drawn on the fused PET/CT
images intending to cover the whole tumor volume. For each ROI the
mean tracer uptake was calculated as percentage of the injected dose
per gram tissue (%ID/g) assuming a tissue density of 1 g/cm3.
2.6. Blocking studies
Blocking studies were performed by tail-vein injection of 125 μg
unlabeled NODAGA-E[c(RGDyK)]2 (Molecular weight: 1707 g/mol;
corresponding to 3 mg c(RGDyK)/kg body weight) 10 min before
tracer injection. Mice bearing U87MG tumors were PET and CT
scanned 1 h pi with either 68Ga- or 64Cu-labeled NODAGA-E
[c(RGDyK)]2 and afterwards sacriﬁced immediately (n = 8 tumors
for each tracer). For calculations of the biodistribution blood, tumors
and major organs were collected, wet-weighted and gamma counted.
Results are presented as %ID/g and correlated to unblocked data(Fig. 7). %ID/g for tumors was calculated from the PET/CT scans
drawing regions of interest using Inveon software.
2.7. Dosimetry projection for humans
For estimation of the human radiation dose for both 68Ga- and
64Cu-labeled NODAGA-E[c(RGDyK)]2 mice biodistribution data were
used. The mean activity in mice organs at 1, 2 and 4 h pi for 68Ga-
(n = 5 mice at each time point), and 1, 4 and 18 h pi for 64Cu-labeled
NODAGA-E[c(RGDyK)]2 (n = 4 mice) was used to calculate Resi-
dence Times (Bq*h/Bq) for each organ. Using the percent kg/g method
with mass extrapolation, 56.9 kg (female) and 73.7 kg (male), data
were extrapolated to human dosimetry. To ensure a conservative
estimate the dynamic bladder model values were set to: urinary
elimination fraction 75% and void interval 5 h. Finally the Effective
Dose (ED) in mSv/MBq for both adult male and female was calculated.
The Organ Level INternal Dose Assessment/EXponential Modeling
software (OLINDA/EXM version 1.1; Vanderbilt University, Nashville,
TN, USA) was used for all calculations [26].
2.8. Statistics
Data are presented as mean ± SEM unless otherwise stated.
Two-sample unequal variance t-test was used. P b 0.05 was
considered signiﬁcant.
3. Results
3.1. Radiochemistry
NODAGA-E[c(RGDyK)]2 (2, 4, 10 and 20 nmol) was labelled with
68GaCl3 eluate to investigate the optimal radiolabelling conditions for
68Ga- NODAGA-E[c(RGDyK)]2 in terms of speciﬁc radioactivity and
radiochemical yield (Fig. 2).
NODAGA-E[c(RGDyK)]2 (2 nmol) was labeled with 68Ga in 15 min
at room temperature with a radiochemical purity of 89%–99% after
SepPak puriﬁcation and a speciﬁc radioactivity of 60 ± 13.7 MBq/
nmol (mean ± SEM) (n = 12).
In separate experiments the radiochemical purity of 68Ga-
NODAGA-E[c(RGDyK)]2 was determined to be N94% in buffer, plasma
and in the ﬁnal formulation 1, 2 and 4 h after incubation.
NODAGA-E[c(RGDyK)]2 was labeled with 64Cu in 15 min at room
temperature with a radiochemical purity of 92%–99% and a speciﬁc
radioactivity of 71.1 ± 7.0 MBq/nmol (mean ± SEM) (n = 8). The
purity of 64Cu-NODAGA-E[c(RGDyK)]2 in buffer was 95% and 90% 1l
;
Fig. 3. Biodistribution data for 68Ga-NODAGA-E[c(RGDyK)]2 in mice 1, 2 and 4 h pi.
Mice were tail-vein injected 4.4 ± 1.4 MBq (mean±SD) under sevoﬂourane anaes-
thesia. Results are shown as %ID/g (mean ± SEM).
Fig. 4. Biodistribution data for 64Cu-NODAGA-E[c(RGDyK)]2 in mice 1, 4 and 18 h pi.
Mice were tail-vein injected 5.2 ± 1.3 MBq (mean±SD) under sevoﬂourane anaes-
thesia. Results are shown as %ID/g (mean ± SEM).
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more than 96% 1, 2, 18, and 24 h after incubation.
3.2. Biodistribution data
For both tracers biodistribution in major organs (liver, kidneys,
lung, spleen, heart, intestine, muscle) and blood was investigated, for
68Ga-NODAGA-E[c(RGDyK)]2 1, 2 and 4 h pi, and for 64Cu-NODAGA-E
[c(RGDyK)]2 1, 4 and 18 h pi (n = 4–6 mice for each tracer). All
tissues were gamma-counted 120 s and %ID/g calculated, corrected
for counting-efﬁciency of the gamma-counter, tracer decay from
injection to counting time, and tissue weight.
For 68Ga-NODAGA-E[c(RGDyK)]2 the highest tracer uptake in %ID/
g (mean±SEM) was in liver 4 h pi (3.68±0.07) with an increase from
1 h pi (2.97 ± 0.39). For kidneys and intestines the highest tracer
uptake was at 1 h pi (2.75 ± 0.14 and 1.82 ± 0.27) decreasing at 2 h
pi (2.11 ± 0.11 and 1.27 ± 0.09) with further decrease for intestine
(0.99 ± 0.18) but same level for kidneys (2.11 ± 0.10) at 4 h pi.
Spleen had stable tracer accumulation during the measured time
points (2.05 ± 0.18, 1.52 ± 0.28, and 1.97 ± 0.27) (Fig. 3).
For 64Cu-NODAGA-E[c(RGDyK)]2 the tracer uptake in all major
organs was highest at 1 h pi decreasing over 4 h to 18 h pi. The
highest %ID/g (mean±SEM) was found at 1 h pi for the kidneys,
intestines, liver and spleen (3.12 ± 0.11, 1.61 ± 0.15, 1.31 ± 0.07,
and 1.15 ± 0.06) decreasing at 4 h pi (1.80 ± 0.15, 1.15 ± 0.08,
1.19 ± 0.15, and 0.72 ± 0.01) and decreasing further at 18 h pi
(1.02 ± 0.05, 0.98 ± 0.11, 0.99 ± 0.09, and 0.81 ± 0.06) (Fig. 4).
3.3. Small animal PET/CT
Both xenograft tumors were clearly visible on PET images for both
NODAGA-E[c(RGDyK)]2 tracers and easy to differentiate from non-
tumoral tissues (Fig. 5).
For 68Ga-NODAGA-E[c(RGDyK)]2 the tracer uptake in tumor – in
%ID/g (mean±SEM) – was highest in U87MG xenografts 1 h pi
2.23 ± 0.08. At 2 h pi the value was 2.02 ± 0.12 at, and at 4 h pi
1.93 ± 0.14 (n = 7-9 tumors). For H727 xenografts we also found
the highest uptake 1 h after injection 1.53 ± 0.06, 1.39 ± 0.05 at 2 h
pi, and declining signiﬁcantly (P b 0.05) to 1.18 ± 0.12 at 4 h pi. For
both xenograft tumor models we found an overall unchanged tracer
uptakewith no signiﬁcant decrease at any time points except for H727
at 4 h pi compared to the level at 1 h pi (Fig. 6 A).
For 64Cu-NODAGA-E[c(RGDyK)]2 the tracer uptake was highest in
U87MG tumors with 2.31 ± 0.15 at 1 h pi, 2.05 ± 0.14 at 4 h pi, and
declining signiﬁcantly (P b 0.001) to 0.52 ± 0.04 at 18 h pi (n = 12–
14). For H727 tumors tracer uptake was 1.48 ± 0.08 at 1 h pi, and
declining signiﬁcantly at 4 and 18 h pi (P b 0.001) to 0.73 ± 0.04 and
0.54 ± 0.07 (Fig. 6 B). Tracer uptake for H727 was decreased
signiﬁcantly already at 4 h pi.3.4. Speciﬁc radioactivity
The speciﬁc radioactivity of the 68Ga labeled tracer using 2 nmol
NODAGAE- NODAGA-E[c(RGDyK)]2 was 60.7 ± 13.7 MBq/nmol
(mean ± SEM) and 16.7 ± 0.3 MBq/nmol using 20 nmol peptide.
Tracer uptake 1 h pi in U87MG tumors in %ID/g (mean ± SEM)
with 2 nmol peptide was 2.23 ± 0.08 (n = 9), and signiﬁcantly (P b
0.001) lower for 20 nmol peptide 0.43 ± 0.04 (n = 10). Tracer
uptake in H727 tumors as %ID/g (mean ± SEM) at same time point
was 1.53 ± 0.06 (n = 10) and 0.32 ± 0.02 (P b 0.001) (n = 12).
Similar results were seen for the PET scans at 2 and 4 h pi (Fig. 7 A-D).
In all the experiments in this study we used similar radioactivity of
both tracers for injection in mice obtaining same, reliable counting
statistic in the PET scans. Regarding similar speciﬁc activities of the
tracers the mice were administrated with different amounts of peptid
due to shorter half-life of 68Ga and due to approximately one hour
elapsed from end of synthesis. For 68Ga-NODAGA-E[c(RGDyK)]2
approximately twice as much peptide as with 64Cu-NODAGA-E
[c(RGDyK)]2 (mean ± SD) 0.197 ± 0.073 nmol versus 0.083 ±
0.010 nmol) was therefore administered.
Using the calculated mean %ID/g of the ROI drawings of the PET/CT
scans for both U87MG and H727 tumors, the Tumor-to-Organ ratios
were calculated assuming good compliance between the twomethods
microPET and gamma-countering.
Tumor-to-Organ ratios using 68Ga-NODAGA-E[c(RGDyK)]2 tracer
were similar for both xenograft tumor models; U87MG tumor-to-
Muscle ratio was (mean±SEM) 6.6 ± 0.4 and H727 tumor-to-Muscle
ratio was 4.6 ± 0.2 at 1 h pi. U87MG tumor-to-Blood ratio was 10.1 ±
0.81 hpi, increasing to 41.9 ± 12.52 hpi, compared toH727 tumor-to-
Blood ratio of 6.5 ± 0.7 1 h pi and 28.8 ± 8.6 2 h pi (Table 1).
Tumor-to-Organ ratios for 64Cu-NODAGA-E[c(RGDyK)]2 tracerwere
quite similar to the ratios found for the 68Ga-NODAGA-E[c(RGDyK)]2
tracer:U87MG tumor-to-Muscle ratiowas (mean±SEM)6.7 ± 0.5, and
H727 tumor-to-Muscle ratio 4.3 ± 0.3 at 1 h pi. The Tumor-to-Blood
ratios were all at a higher level: U87MG tumor-to-Blood ratio was
23.4 ± 1.0 1 h pi, increasing to 128.5 ± 3.7 4 h pi, and H727 tumor-to-
Blood ratio 15.0 ± 0.7 1 h pi and 45.7 ± 1.3 4 h pi (Table 2).
3.5. Blocking studies
The integrin αVβ3 receptor speciﬁcity of 68Ga- and 64Cu-labeled
NODAGA-E[c(RGDyK)]2 tracers was tested in a blocking study with
administration of cold NODAGA-E[c(RGDyK)]2, corresponding to
approximately 3 mg c(RGDyK) per kg body weight, injected 10 min
before the respective tracers. For 68Ga-NODAGA-E[c(RGDyK)]2 the
tracer uptake inU87MG, calculated as%ID/g (mean±SEM) from the PET
scans 1 h pi, was reduced signiﬁcantly (Pb 0.001) from 2.23 ± 0.08
(n = 9) to 0.20 ± 0.03 (n = 8), and for 64Cu-NODAGA-E[c(RGDyK)]2
reduced signiﬁcantly (Pb 0.001) from 2.31 ± 0.15 (n = 14) to 0.39 ±
Fig. 5. PET/CT images of mice bearing U87MG or H727 xenograft tumors, A) Mice scanned for 15 min with 4.8 ± 0.9 MBq (mean±SD) 68Ga-NODAGA-E[c(RGDyK)]2 at 1, 2 and 4 h
post injection, and B) Mice scanned for 20 min with 5.0 ± 1.0 MBq 64Cu-NODAGA-E[c(RGDyK)]2 at 1, 4, 18 h pi. Both coronal and axial slides are shown from a candidate mouse
representing each tracer and tumor type. Tumors are marked with white arrows.
Fig. 6. A) 68Ga-NODAGA-E[c(RGDyK)]2 tracer uptake in U87MG and H727 xenograft tumor models. For H727 tumors a signiﬁcant decreased tracer uptake was found from 1 to 4 h pi
(P b 0.05). B) 64Cu-NODAGA-E[c(RGDyK)]2 tracer uptake in U87MG and H727 xenograft tumor models. For U87MG tumors a signiﬁcant decreased tracer uptake was found from 1 to
18 h pi, and from 4 to 18 h pi (both P b 0.001). For H727 tumors a signiﬁcant decreased tracer uptake was found from 1 to 4 h pi, from 1 to 18 h pi (both P b 0.001), and from 4 to 18 h
pi (P b 0.05). Results are shown as %ID/g (mean±SEM).
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Fig. 7. Mice bearing human U87MG xenograft tumors (white arrows). PET scans were performed 1 h after injection of 68Ga-NODAGA-E[c(RGDyK)]2. A) 2 nmol NODAGA-E
[c(RGDyK)]2 used for labeling, resulting in a speciﬁc radioactivity of the tracer at 60.7 ± 13.7 MBq/nmol. B) 20 nmol NODAGA-E[c(RGDyK)]2 used for labeling, resulting in a speciﬁc
radioactivity of 16.7 ± 0.3 MBq/nmol. Tracer uptake in U87MG tumors (C) and H727 tumors (D) with 68Ga-labeled tracer based on 2 or 20 nmol NODAGA-E[c(RGDyK)]2 peptide.
Results from PET scans at 1, 2 and 4 h post injection are shown in %ID/g (mean±SEM). ***): P b 0.001 for 2 versus 20 nmol peptide, at same time points and same xenograft tumor.
264 J. Oxboel et al. / Nuclear Medicine and Biology 41 (2014) 259–2670.10 (n = 8) (Fig. 8 A and B). Administration of cold peptide also
inﬂuenced the tracer uptake in all major organs showing a decreased
tracer activity, except for 68Ga-NODAGA-E[c(RGDyK)]2 in liver where a
1.8 fold increase was observed (Fig. 8C and D).3.6. Radiation Dosimetry
Residence times based on biodistribution data from both 68Ga-
NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 tracers areTable 1
Tumor-to-Organ ratios for 68Ga-NODAGA-E[c(RGDyK)]2 at 1, 2 and 4 h pi; using U87MG an
68Ga-NODAGA-E[c(RGDyK)]2
Tumor-to-Organ Ratios
1 h pi 2 h p
H727 U87MG H727
Tumor-to-blood 6.5 ± 0.7 10.1 ± 0.8 28.8 ±
Tumor-to-liver 0.3 ± 0.1 0.8 ± 0.2 0.7 ±
Tumor-to-kidney 0.6 ± 0.03 0.8 ± 0.04 0.7 ±
Tumor-to-intestine 0.9 ± 0.2 1.4 ± 0.2 1.4 ±
Tumor-to-Muscle 4.6 ± 0.2 6.6 ± 0.4 6.1 ±
Table 2
Tumor-to-Organ ratios for 64Cu-NODAGA-E[c(RGDyK)]2 at 1, 4 and 18 h pi; using U87MG a
64Cu-NODAGA-E[c(RGDyK)]2
Tumor-to-Organ Ratios
1 h pi 4 h p
H727 U87MG H727
Tumor-to-blood 15.0 ± 0.7 23.4 ± 1.0 45.7
Tumor-to-liver 1.1 ± 0.1 1.8 ± 0.1 0.7
Tumor-to-kidney 0.5 ± 0.02 0.8 ± 0.02 0.4
Tumor-to-intestine 0.9 ± 0.1 1.5 ± 0.1 0.6
Tumor-to-Muscle 4.3 ± 0.3 6.7 ± 0.5 4.2shown in Table 3. Table 4 shows the calculated estimates of human
radiation-absorbed doses using OLINDA/EXM, and the total effective
doses (ED). The highest radiation-absorbed doses were found in the
urinary bladder wall: for 68Ga-NODAGA-E[c(RGDyK)]2 0.016 and
0.012 mGy/MBq for females and males, for 64Cu-NODAGA-E
[c(RGDyK)]2 0.020 and 0.015 mGy/MBq, respectively. This estimate
was conservative because the dynamic bladder model values were set
to a urinary elimination fraction of 75% and a void interval of 5 h. The
whole body ED was for 68Ga-NODAGA-E[c(RGDyK)]2 0.035 and
0.026 mSv/MBq for females and males, and for 64Cu-NODAGA-Ed H727 xenograft tumors. Results are shown as mean ± SEM.
i 4 h pi
U87MG H727 U87MG
8.6 41.9 ± 12.5 20.8 ± 7.2 34.0 ± 11.8
0.1 1.1 ± 0.2 0.3 ± 0.00 0.5 ± 0.01
0.04 1.0 ± 0.05 0.6 ± 0.03 0.9 ± 0.05
0.2 2.0 ± 0.2 1.5 ± 0.4 2.5 ± 0.6
0.4 8.9 ± 0.6 5.9 ± 0.5 9.6 ± 0.8
nd H727 xenograft tumors. Results are shown as mean ± SEM.
i 18 h pi
U87MG H727 U87MG
± 1.3 128.5 ± 3.7 14.9 ± 1.1 14.3 ± 1.1
± 0.1 2.1 ± 0.1 0.6 ± 0.04 0.5 ± 0.04
± 0.03 1.3 ± 0.1 0.5 ± 0.03 0.5 ± 0.03
± 0.03 2.0 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
± 0.2 12.8 ± 0.5 4.1 ± 0.2 3.9 ± 0.2
Fig. 8. Blocking with 3 mg c(RGDyK) per kg bodyweight followed by PET scan with 68Ga-NODAGA-E[c(RGDyK)]2 or 64Cu-NODAGA-E[c(RGDyK)]2. Tracer uptake: A) 68Ga-NODAGA-E
[c(RGDyK)]2 and B) 64Cu-NODAGA-E[c(RGDyK)]2 in U87MG xenograft tumors with and without blocking with cold peptide. Results are shown as %ID/g (mean ± SEM), P 0.001.
Tracer uptake: C) 68Ga-NODAGA-E[c(RGDyK)]2 and D) 64Cu-NODAGA-E[c(RGDyK)]2 in normal organs and blood with and without blocking with cold peptide. Results are shown as
%ID/g (mean ± SEM).
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administered dose of 200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 or 64Cu-
NODAGA-E[c(RGDyK)]2 to humans would lead to an estimated
radiation burden of 5.2 to 10 mSv (Table 4).
4. Discussion
Several RGD peptides labeled with isotopes for PET imaging have
been proposed as useful ligands for integrin αvβ3 imaging [27–29].
The translation into clinic use of promising candidates such as 18 F-
galacto-RGD has however been hampered by complicated multi-step
radiochemistry difﬁcult to automate [22]. Intense interest in devel-
oping radiolabelled RGD peptides conjugated to bifuntional chelators
has therefore been pursued due to the simple radiolabelling pro-
cedures and availability of the radio metals.
In the present study we produced and evaluated two new PET
tracers for imaging tumor neo-angiogenesis, and found promising
imaging and dosimetry characteristics. The tracers are dimeric
c(RGDyK) peptides conjugated with NODAGA and labeledwith either
64Cu or 68Ga. Previous studies have shown high receptor-afﬁnity toTable 3
Residence times (Bq*h/Bq) in the main target organs for both 68Ga-NODAGA-E
[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2. Data based on biodistribution in
mouse organs.
Target Organ Residence time (Bq*h/Bq)
68Ga-NODAGA-RGD-dimér 64Cu-NODAGA-RGD-dimér
Female Male Female Male
Heart Wall 3.83E-03 3.90E-03 6.08E-03 6.13E-03
Kidneys 1.16E-02 9.76E-03 7.72E-02 6.48E-02
Liver 1.77E-01 1.33E-01 1.47E-01 1.53E-01
Lungs 7.98E-03 7.69E-03 5.14E-02 4.95E-02
Muscle 6.00E-02 7.36E-02 2.81E-01 3.59E-01
Small Intestine 1.01E-02 8.68E-03 6.65E-02 5.79E-02
Spleen 6.49E-03 6.11E-03 1.31E-02 1.22E-02
Remainder Body 1.49E + 00 1.49E + 00 1.73E + 01 1.70E + 01integrin αVβ3 for both c(RGDfK) and c(RGDyK)—the most often used
RGD peptides for tracer labeling [7,8,10–17,20–23]. However
c(RGDyK) shows higher tracer uptake in xenograft tumors probably
due to the increased hydrophilicity of the D-Tyrosine (D-Tyr)
compared to the D-Phenylalanine (D-Phe) derivative of c(RGDfK),
and also faster renal excretion [8,16].
The afﬁnity of c(RGDyK) or c(RGDfK) tracers targeting integrin
αVβ3 is similar for both NODAGA- and DOTA-conjugated peptides,
showing that the replacement of DOTA chelators with the NODAGA
chelator has no inﬂuence on binding afﬁnity or receptor speciﬁcity
[11,15]. Advantages of NODAGA conjugated tracers are the increased
Tumor-to Background and Tumor-to-Blood ratios with rapid renal
excretion caused by higher hydrophilicity of NODAGA and high in vivo
stability of both 68Ga and 64Cu chelates [15,19]. Studies with 68 Ga/
64Cu-labeled monomeric, dimeric, tetrameric or octameric RGD
peptides showed increased receptor-binding afﬁnity and speciﬁcity
for integrinαVβ3, enhanced tumor uptake and longer tumor retention
with increased numbers of RGD peptides, but also tracer accumulation
in the kidneys, resulting in poorer Tumor-to-Kidney ratios [16,17].
Regarding Tumor-to-Background ratios there was no signiﬁcant
advantage in using radiolabeled tetrameric or octameric RGD peptides
over the dimeric RGD peptides [19]. Thus dimeric RGD peptides were
concluded to be the best candidates for further investigation for
potential clinical translation. Initial attempts to synthesize 68Ga-
NODAGA-E[c(RGDyK)]2 using the preconcentration approach where
the 68Ga-eluate is trapped on an ion exchange column and elutedwith
acetone/HCl mixture failed due to formation of large amounts of
unknown biproducts. Therefore the fractionated approach [24] was
tested and the radiolabelling was straightforward. To optimize the
speciﬁc activity of 68Ga-NODAGA-E[c(RGDyK)]2 the labeling efﬁcien-
cy as a function of amount of precursor was also investigated (Fig. 2).
To obtain optimal speciﬁc radioactivity 2 nmol of peptide was
selected since lower amounts of peptide did not give reliable results.
The relative large variation in the SA of 68Ga-NODAGA-E[c(RGDyK)]2
(16–153 MBq/nmol) is a consequence of the variation on the
radiochemical yield.
Table 4
OLINDA estimated radiation-absorbed doses for human adults after injection of 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2, respectively. Given a tracer dose of
200 MBq in patients, the radiation burden would be 5.2–6.9 mSv for 68Ga-NODAGA-E[c(RGDyK)]2, and 7.7–10.0 mSv for 64Cu-NODAGA-E[c(RGDyK)]2.
OLINDA estimated radiation-absorbed doses for human adults
Taget Organ Organ doses (mGy/MBq)
68Ga-NODAGA-RGD-dimér 64Cu-NODAGA-RGD-dimér
Adult female Adult male Adult female Adult male
Adrenals 9.97E-05 7.58E-05 1.78E-04 1.37E-04
Brain 8.64E-05 7.00E-05 1.77E-04 1.42E-04
Breasts 8.04E-04 6.31E-04 1.56E-03 1.22E-03
Gallbladder Wall 0.00E + 00 0.00E + 00 0.00E + 00 0.00E + 00
Lower large Intestine Wall 2.65E-03 2.07E-03 5.15E-03 3.95E-03
Small Intestine 1.25E-04 1.04E-04 2.17E-04 1.84E-04
Stomach Wall 2.27E-03 1.78E-03 4.34E-03 3.42E-03
Upper large Intestine Wall 1.03E-04 8.07E-05 1.97E-04 1.54E-04
Heart Wall 0.00E + 00 0.00E + 00 0.00E + 00 0.00E + 00
Kidneys 1.28E-04 9.93E-05 1.63E-04 1.28E-04
Liver 3.41E-03 1.95E-03 8.65E-04 6.65E-04
Lungs 1.22E-03 9.16E-04 1.69E-03 1.32E-03
Muscle 3.85E-05 3.04E-05 6.49E-05 5.22E-05
Ovaries/Testes 4.33E-03 3.43E-03 8.32E-03 6.56E-03
Pancreas 4.73E-05 3.62E-05 7.10E-05 5.77E-05
Red Marrow 1.76E-03 1.44E-03 3.55E-03 2.84E-03
Osteogenic Cells 2.66E-04 1.98E-04 7.43E-04 5.52E-04
Skin 1.51E-04 1.19E-04 2.97E-04 2.31E-04
Spleen 1.26E-04 9.76E-05 8.55E-05 6.66E-05
Thymus 8.78E-05 6.70E-05 1.69E-04 1.28E-04
Thyroid 8.22E-04 6.68E-04 1.66E-03 1.33E-03
Urinary Bladder Wall 1.59E-02 1.19E-02 2.04E-02 1.53E-02
Uterus 1.24E-04 1.02E-04 2.29E-04 1.88E-04
Total Body 0.00E + 00 0.00E + 00 0.00E + 00 0.00E + 00
Effective Dose (mSv/MBq) 3.46E-02 2.59E-02 5.01E-02 3.86E-02
mSv, for 200 MBq dose 6.92E + 00 5.18E + 00 1.00E + 01 7.72E + 00
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peptide was straightforward giving robust results.
In the side-by-side comparison between 68Ga-NODAGA-E
[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 we found a similar
tracer uptake in U87MG and H727 tumors (~2.3%ID/g and ~1.5%ID/g
respectively) 1 h pi. The tracer retention was constant for both
U87MG and H727 tumors with 68Ga-NODAGA-E[c(RGDyK)]2 over the
time period from 1 to 4 h pi, and also for 64Cu-NODAGA-E[c(RGDyK)]2
in U87MG tumors from 1 to 4 h pi. For H727 tumors a decrease was
found with both tracers from 1 to 4 h pi. When imaging at 18 h pi,
only relevant for 64Cu-NODAGA-E[c(RGDyK)]2, decreased tracer
uptake were found for both tumors (Fig. 5). More importantly, there
was no increase in any of the Tumor-to-Organs ratio from 4 to 18 h pi
making delayed imaging at 18 h unnecessary. In a previous study
where we investigated 64Cu-NODAGA-c(RGDyK), we also found a
signiﬁcant decrease in tracer uptake from 1 to 4 and 18 h pi in H727
xenograft tumors [21]. Tracer uptake of 68Ga-NOTA- E[c(RGDyK)]2
[17] showed similar tracer uptake in U87MG tumors (2.2%ID/g 1 h pi
and 1.7%ID/g at 2 h pi) indicating that choice of chelator has no
inﬂuence on the tracer uptake.
In the present study both dimeric NODAGA-E[c(RGDyK)]2 tracers
showed similar uptake in non-tumoral organs, with exception of a
high 68Ga- NODAGA-E[c(RGDyK)]2 uptake in liver. A high uptake in
liver is normally explained by higher hydrophobicity of the tracer
resulting in rapid hepatobiliary excretion [14,18,22]. Apart from this
exception the highest uptake in normal tissues was in the kidneys
indicating the predominance of the renal excretion route. We found
an increased kidney uptake for 64Cu-NODAGA-E[c(RGDyK)]2 com-
pared to what we previously found for the monomeric RGD tracer
64Cu-NODAGA-c(RGDyK) [21], resulting in minor but similar de-
creased Tumor-to-Kidney ratios for both investigated dimeric
c(RGDyK) tracers. Mouse kidneys have high integrin αVβ3 expression
on endothelial cells of small glomerulus vessels, indicating that the
renal uptake of c(RGDxK) tracers is integrin αVβ3 speciﬁc. The
increased kidney uptake from monomeric to dimeric c(RGDxK) canpartly be explained by increased αVβ3-binding afﬁnity [16]. An
optimal radiotracer should, together with an early and high tumor
uptake and a high tumor-to-background ratio, have a fast blood
clearance. Regarding Tumor-to-Blood ratios 64Cu-NODAGA-E
[c(RGDyK)]2 showed higher ratios than 68Ga- NODAGA-E
[c(RGDyK)]2, but Tumor-to-Muscle (background) was similar for
both dimeric c(RGDyK) tracers.
Effective blocking of integrin αVβ3 receptors with cold NODAGA-E
[c(RGDyK)]2 conﬁrmed the speciﬁcity of the dimeric E[c(RGDyK)]2
tracers in both U87MG and H727 xenograft tumors (Fig. 8).
In small animals, where the distribution volume is small, and the
number of human receptors in xenograft tumors is limited, high SA is
preferable in order to obtain high tracer uptake in tumors and
sufﬁcient contrast in PET images between target tissue and its
surroundings [30]. In the literature SA of 68Ga- and 64Cu-c(RGDxK)-
conjugates, varying from 10 to 550 MBq/nmol, reported all good
tracer uptake in the tumors [12,15–17,21,22].
In the present study we investigated different levels of SA for 68Ga-
NODAGA-E[c(RGDyK)]2 and found an SA of 60 MBq/nmol was
sufﬁcient for a high tracer uptake (N2% ID/g), whereas a lower SA
(16 MBq/nmol) resulted in a signiﬁcantly decreased tracer uptake
(0.5% ID/g) which is unsuitable for imaging purposes (Fig. 7). Similar
tracer uptake (N2%ID/g) was found for 64Cu-NODAGA-E[c(RGDyK)]2
with a speciﬁc activity of 71 MBq/nmol.
Taken together both 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-
NODAGA-E[c(RGDyK)]2 seem promising for future clinical use, with
their individual speciﬁc advantages. We therefore performed esti-
mates of dosimetry in humans based on projections from the mice
data and found a favorable radiation burden of 10 mSv or less when
administrated in a relevant dose of 200 MBq (Table 4).
5. Conclusion
68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 are
promising new candidates for PET imaging of integrin αVβ3 receptor
267J. Oxboel et al. / Nuclear Medicine and Biology 41 (2014) 259–267positive tumors. The two dimeric NODAGA-c(RGDyK) tracers showed
higher integrin αVβ3 binding afﬁnity compared to the monomeric
NODAGA-c(RGDyK) tracers. Compared to 64Cu-NODAGA-E
[c(RGDyK)]2, 68Ga-NODAGA-E[c(RGDyK)]2 showed a slightly more
stable tumor retention for both U87MG and H727 xenograft tumors.
Both tracers showed favorablehuman radiationburdenestimates of less
than 10 mSv calculated for a realistic clinical dose of 200 MBq.
Due to the better tumor retention and advantage of in-house
commercially available 68 Ge/68Ga generators, 68Ga-NODAGA-E
[c(RGDyK)]2 may be the most promising candidate for clinical
translation into humans for PET imaging neo-angiogenesis in many
common cancer types.
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